





[Home](#)

## *Funding Opportunity Details*

### Exploratory Studies in Cancer Detection, Diagnosis, and Prognosis

ID & Mechanism: **PA-08-267 R21** [View in NIH Guide](#)Application Status: **Accepting new applications**Release Date: **2008-09-23**Application Receipt Dates: **2009-02-16, 2009-06-16, 2009-10-16, 2010-02-16, 2010-06-16, 2010-10-16, 2011-02-16, 2011-06-16, 2011-10-16, 2012-02-16, 2012-06-16**

#### Page Options

-  [Printer Friendly](#)
-  [E-mail This Page](#)
-  [Save as Tab Delimited Text](#)
-  [RTF / Word Document](#)

[View Funding Opportunity Codes](#) | [View Funding Opportunity History](#) | [View Contacts](#) |

New biomarkers and laboratory assays are needed for cancer screening and risk assessment, for pathologic characterization of malignant tumors and assessment of disease prognosis, and for prediction and measurement of response to treatments, particularly with novel therapeutic or chemopreventive agents. The major goal of this initiative is to promote the initial evaluation of new molecular or cellular characteristics of premalignant cells or tumors or the development of assays that will be useful for cancer detection, diagnosis, and/or prognosis. Investigators are encouraged to pursue new clinical insights and consider the full array of potentially informative biological characteristics of tumor cells and tissues. The applicant should provide a strong rationale for proposing that a particular biomarker or assay has the potential to address a significant clinical problem. This initiative is intended to support translational studies that identify promising new means for cancer detection and diagnosis and provide the initial, critical information necessary to decide whether potential clinical utility justifies further investment.

[Back to Top](#)

This funding opportunity is coded as follows:

#### Common Scientific Outline

- 4.1** Early Detection, Diagnosis, and Prognosis - Technology Development and/or Marker Discovery
- 4.2** Early Detection, Diagnosis, and Prognosis - Technology and/or Marker Evaluation with Respect to Fundamental Parameters of Method

#### Type of Cancer

- 2** - Not Site-Specific Cancer

[Back to Top](#)

### Funding Opportunity History

2008-09-23	<a href="#">PA-08-267</a>	replaces	<a href="#">PA-06-299</a>
2006-03-30	<a href="#">PA-06-299</a>	replaces	<a href="#">PA-05-165</a>
2005-09-16	<a href="#">PA-05-165</a>	replaces	<a href="#">PA-03-003</a>
2002-10-03	<a href="#">PA-03-003</a>	replaces	<a href="#">PA-98-022</a>
2002-10-03	<a href="#">PA-03-003</a>	replaces	<a href="#">PA-01-010</a>
2000-10-31	<a href="#">PA-01-010</a>	replaces	<a href="#">PA-98-022</a>

[Back to Top](#)

---

## Contacts

Name	Email
Dr. Heng Xie	<a href="mailto:xieh@mail.nih.gov">xieh@mail.nih.gov</a>
Dr. James Tricoli	<a href="mailto:tricolij@mail.nih.gov">tricolij@mail.nih.gov</a>
Karl Krueger Ph.D.	<a href="mailto:kruegerk@mail.nih.gov">kruegerk@mail.nih.gov</a>

[Back to Top](#)

[Contact Us](#) | [Dictionary](#) | [Policies](#) | [Accessibility](#) | [Site Map](#)  
A Service of the National Cancer Institute

